16 September 2026 editorial review · Item
IMMUNOSTEM PD-L1 HSPC gene therapy: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: IMMUNOSTEM remains not yet recruiting after its estimated 2025 start. Mouse PD-L1 restoration does not establish human immune tolerance, durability or conditioning requirements. No human outcome was located.
- Registry NCT06938334: NOT_YET_RECRUITING; updated 2025-04-22; enrollment 15 (ESTIMATED); primary completion 2029-06-15 (ESTIMATED); results not posted in retrieved record.
- Programme/sponsor/conference source boundary: Altheia Science — PD-L1 HSPC technology (manufacturer); Altheia Science publications: PD-L1 overexpression in HSPCs and autoimmune diabetes (manufacturer).